Psilocybin for Treatment-Resistant Depression

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression.

This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve.

This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants’ depressive symptoms and side effects will also be measured during the study.

Topic Treatment-Resistant Depression Depression
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Canadian Rapid Treatment Centre of Excellence
Established in 2018 the Canadian Rapid Treatment Centre of Excellence offers ketamine therapy to aid those suffering from several treatment-resistant conditions such as depression and bipolar disorder.

Braxia Scientific
Braxia Scientific Corp (previously Champignon Brands and Apotheosis Scientific) is one of the for-profit companies developing therapies in conjunction with psychedelics. In its short history, it has acquired a psilocybin research firm Tassili Life Sciences, a mushroom cultivator (Artisan Growers), and has recently started offering esketamine treatments for MDD.

Brain and Cognition Discovery Foundation
This company doesn't have a full profile yet, it is linked to a clinical trial.

Papers

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
This open-label waitlist trial (n=30) assessed the feasibility of psilocybin-assisted psychotherapy (PAP/PAT) in a complex population with treatment-resistant depression (TRD), including major depressive and bipolar II disorders, baseline suicidality, and significant comorbidity. Participants received one, two, or three sessions of PAP with psilocybin (25mg), accompanied by preparation and integration psychotherapy sessions. Immediate treatment showed greater reductions in depression severity (MADRS) compared to the waitlist period, with a large effect size (g = 1.07, p < 0.01). Repeated doses were associated with further reductions in depression severity. Adverse events were transient, and the study demonstrated feasibility, preliminary antidepressant efficacy, safety, and tolerability in this population.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.